Table 1

Characteristics of patients with CVD and controls

Case groupControl groupStandardised difference
(N=39 648)(N=39 648)
N (%)N (%)
Age
 Mean (SD)78.6 (7.3)78.5 (7.3)
Sex
 Male21 551 (54.4)21 551 (54.4)
 Female18 097 (45.6)18 097 (45.6)
Complications
Type 2 diabetes mellitus6322 (15.9)4651 (11.7)0.122
Essential (primary) hypertension13 368 (33.7)9799 (24.7)0.199
Atrial fibrillation and flutter3256 (8.2)1113 (2.8)0.239
Chronic kidney disease2711 (6.8)1164 (2.9)0.182
Disorders of lipoprotein metabolism and other lipidaemias6566 (16.6)4873 (12.3)0.122
Knee osteoarthritis2416 (6.1)2033 (5.1)0.042
Hip osteoarthritis493 (1.2)433 (1.1)0.014
Hand osteoarthritis53 (0.1)50 (0.1)0.002
Concomitant medication
Oral antidiabetic drugs5150 (13.0)3428 (8.6)0.14
Platelet aggregation inhibitors6712 (16.9)2807 (7.1)0.307
Diuretic5212 (13.1)1951 (4.9)0.29
Beta-blocking agents4058 (10.2)1063 (2.7)0.311
Calcium antagonists10 559 (26.6)6183 (15.6)0.273
Agents acting on the renin–angiotensin system9256 (23.3)5263 (13.3)0.263
Lipid-regulating/antiatheroma preparations7339 (18.5)4555 (11.5)0.198
  • CVD, cardiovascular disease.